<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218436</url>
  </required_header>
  <id_info>
    <org_study_id>CAP CIN</org_study_id>
    <nct_id>NCT03218436</nct_id>
  </id_info>
  <brief_title>Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia</brief_title>
  <acronym>CAPCIN</acronym>
  <official_title>Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Women's Hospital Tübingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Women's Hospital Tübingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in
      the plasma cohort compared to watchful waiting in the control cohort.

      Primary endpoint after 3-6 months: Pathological remission.

      Secondary endpoint: HPV remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological remission of cervical intraepithelial neoplasia</measure>
    <time_frame>3-6 months</time_frame>
    <description>Biopsy, Histopathological examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human papilloma virus remission rate</measure>
    <time_frame>3-6 months</time_frame>
    <description>Smear testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort / Dyscomfort during intervention</measure>
    <time_frame>Immediately, 2 week, 3-6 months</time_frame>
    <description>Freiburger Index of patient comfort</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>CAP cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cold Atmospheric plasma intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CAP treatment</intervention_name>
    <description>Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.</description>
    <arm_group_label>CAP cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for CAP:

          -  Histologically confirmed CIN I / II

          -  Reliable assessment of the radius of the portio and marginal borders of the lesions

          -  Written consent for treatment with low temperature plasma after reconnaissance

        Inclusion Criteria for Control-Group:

          -  Histologically confirmed CIN I / II

          -  Reliable assessment of the radius of the portio and marginal borders of the lesions

          -  Patients who want a waiting procedure and a control examination after 3-6 months

        Exclusion Criteria:

          -  Histologically confirmed CIN III

          -  Not fully visible transformation zone

          -  An indication of invasive disease

          -  Expected lack of compliance of the patient or incapacity of the patient to understand
             the meaning and purpose of the clinical trial

          -  Severe cardio-vascular disease

          -  Lack of patient consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Henes, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Women's Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Henes, Dr.</last_name>
    <phone>+49 70712982211</phone>
    <email>melanie.henes@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Weiss, Dr.</last_name>
    <phone>+49 70712982211</phone>
    <email>martin.weiss@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department for Women's Health</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Linneweh, Dr</last_name>
      <phone>004970712985380</phone>
      <email>miriam.linneweh@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

